Introduction Pituitary adenomas with cavernous sinus invasion represent a challenging subset of intracranial tumors. The presence of cavernous sinus invasion complicates surgical resection and increases the risk of recurrence and postoperative complications. Endoscopic endonasal surgery (EES) has emerged as a promising alternative to traditional microscopic transsphenoidal surgery, offering enhanced visualization and reduced collateral damage. This meta-analysis aims to evaluate the efficacy and safety of EES in the treatment of pituitary adenomas with cavernous sinus invasion, focusing on remission rates, gross total resection (GTR), recurrence rates, and complications.

Methods A comprehensive literature search was conducted through PubMed, Scopus, Embase, and CENTRAL databases until August 2025, following PRISMA guidelines. Studies meeting eligibility criteria, including human studies published in English and involving adult patients with pituitary adenomas and cavernous sinus invasion treated with EES, were included. Data extraction focused on patient demographics, tumor characteristics, surgical outcomes, and complications. Statistical analysis was performed using a random-effects model, and subgroup analysis was conducted based on factors such as tumor size, Knosp grade, and hormonal subtype.

Results A total of 27 studies involving 3,591 patients were included. The pooled remission rate was 60% (95% CI: 49% to 71%), with substantial variability across studies. The pooled residual tumor rate was 15% (95% CI: 11% to 19%), and the recurrence rate was 8% (95% CI: 6% to 11%). The incidence of cerebrospinal fluid (CSF) leaks was 9% (95% CI: 3% to 14%), while the rates of ICA injury and cranial nerve injury were extremely low (0.00% and 0.01%, respectively). Subgroup analyses revealed higher remission rates in macroadenomas (68%) compared to microadenomas (33%), and GH-secreting tumors showed higher endocrinological remission rates compared to ACTH-secreting tumors.

Conclusion Endoscopic endonasal surgery demonstrates moderate efficacy in the treatment of pituitary adenomas with cavernous sinus invasion, with favorable remission and resection rates. However, substantial variability across studies emphasizes the need for further standardization of surgical techniques and patient selection criteria. The procedure is generally safe, with low rates of serious complications such as ICA injury and cranial nerve damage. Further prospective studies are needed to optimize patient management and evaluate long-term outcomes, including recurrence and quality of life.

The authors have declared no competing interest.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251108949

none

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

supplementary file